Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $6.4 million.

  • Neurocrine Biosciences' Depreciation & Amortization (CF) rose 322.58% to $6.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $26.0 million, marking a year-over-year increase of 1063.83%. This contributed to the annual value of $26.0 million for FY2025, which is 1063.83% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Depreciation & Amortization (CF) is $6.4 million, which was up 322.58% from $6.7 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Depreciation & Amortization (CF) registered a high of $6.7 million during Q3 2025, and its lowest value of $2.5 million during Q1 2021.
  • In the last 4 years, Neurocrine Biosciences' Depreciation & Amortization (CF) had a median value of $5.6 million in 2024 and averaged $5.4 million.
  • In the last 5 years, Neurocrine Biosciences' Depreciation & Amortization (CF) skyrocketed by 5238.1% in 2024 and then crashed by 156.25% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Depreciation & Amortization (CF) stood at $2.5 million in 2021, then surged by 96.0% to $4.9 million in 2023, then increased by 26.53% to $6.2 million in 2024, then increased by 3.23% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q4 2025, $6.7 million for Q3 2025, and $6.3 million during Q2 2025.